title: PCSK9 Inhibitors: A Technology Worth Paying For?
authors.affiliation: Christiana Care Health System, Newark, DE, 19317, USA. wweintraub@christianacare.org.
authors.forename: William S
authors.initials: WS
authors.lastname: Weintraub
authors.affiliation: AI DuPont-Nemours Hospital for Children, Wilmington, DE, USA.
authors.forename: Samuel S
authors.initials: SS
authors.lastname: Gidding
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004791:Enzyme Inhibitors / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D000091362:PCSK9 Inhibitors; D000071449:Proprotein Convertase 9
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents; D004791:Enzyme Inhibitors; D000091362:PCSK9 Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; C577155:evolocumab; C571059:alirocumab